Macrophage Anticancer Therapy Market Size, Share & Forecast 2026-2032: Engineering the Innate Immune System for Solid Tumor Immunotherapy
The immuno-oncology revolution has achieved its most dramatic successes in hematologic malignancies—liquid tumors where chimeric antigen receptor T cells can directly access malignant cells circulating in blood and bone marrow. Yet solid tumors, which constitute over 90% of all cancer diagnoses and cancer-related mortality, remain stubbornly resistant to adoptive T cell immunotherapy. The fundamental obstacle is not antigen recognition but immune cell access: solid tumors construct a formidable physical and immunosuppressive barrier—a dense fibrotic stroma, abnormal vasculature, hypoxic gradients, and a cytokine milieu dominated by transforming growth factor-beta and interleukin-10 that collectively repels, inactivates, or exhausts infiltrating T cells. Macrophage anticancer therapy addresses this solid tumor challenge through a fundamentally differentiated immunological mechanism that exploits the natural tumor-homing behavior of macrophages. Unlike T cells, macrophages are actively recruited by tumors through chemokine gradients—the very signals that malignancies emit to recruit tumor-associated macrophages for their own support—and naturally infiltrate even the most fibrotic and hypoxic tumor cores. By engineering macrophages with chimeric antigen receptors that redirect their intrinsic phagocytic and cytotoxic capacity against tumor cells, or by reprogramming immunosuppressive tumor-associated macrophages toward an inflammatory, antitumor phenotype, this emerging therapeutic modality is positioned to succeed where T cell therapies have struggled. As the clinical pipeline of CAR-M and engineered macrophage products advances, this nascent market is projected to grow from USD 436 million to USD 635 million by 2032 at a 5.6% CAGR.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Macrophage Anticancer Therapy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Macrophage Anticancer Therapy market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6066178/macrophage-anticancer-therapy
Market Valuation and Product Architecture: The Biology of Engineered Phagocytosis
The global market for Macrophage Anticancer Therapy was estimated to be worth USD 436 million in 2025 and is projected to reach USD 635 million, growing at a CAGR of 5.6% from 2026 to 2032. This growth trajectory reflects the early-stage, pre-commercial nature of the engineered macrophage therapy field, where value is concentrated in research and development investment, preclinical services, and early-phase clinical trial activity rather than commercial product revenue. Macrophage anticancer therapy is an immunotherapy that utilizes the anticancer activity of macrophages. Macrophages are important cells in the immune system with multiple functions, including phagocytosis, killing of pathogens and tumor cells, and regulation of immune responses. In macrophage anticancer therapy, macrophages are activated or modified to more effectively recognize and attack tumor cells. This therapy can be achieved through various routes, such as direct injection of activated macrophages into the tumor site or using gene engineering techniques to modify macrophages to have stronger anticancer abilities. Macrophage anticancer therapy provides new ideas and methods for tumor treatment and brings hope to cancer patients. The therapeutic macrophage engineering process involves several distinct technological approaches: chimeric antigen receptor macrophage (CAR-M) generation, in which macrophages are transduced with CAR constructs typically targeting solid tumor antigens such as HER2 or mesothelin, redirecting their innate phagocytic machinery against malignant cells; cytokine-mediated polarization, in which macrophages are ex vivo activated with interferon-gamma, toll-like receptor agonists, or CD40 ligand to adopt an M1-like inflammatory antitumor phenotype; and in vivo reprogramming, in which small molecules, antibodies, or nanoparticles target tumor-associated macrophages to shift them from an immunosuppressive M2-like state toward tumoricidal function.
Target Antigen Landscape and Solid Tumor Focus
The CAR-M therapy field is stratified by target antigen selection, a strategic decision with profound implications for tumor type applicability and safety profile. CD19-directed macrophage therapy, while representing the most validated CAR target from T cell therapy experience, primarily serves as a proof-of-concept demonstration given that CD19-expressing B cell malignancies are already effectively addressed by CAR-T therapy. HER2-directed macrophage therapy represents the most clinically advanced solid tumor targeting strategy, with Carisma Therapeutics’ CT-0508, an adenovirally transduced autologous macrophage product, having demonstrated safety and preliminary evidence of biological activity in Phase I clinical trials. A significant 2026 milestone involves the expansion of clinical investigation into additional solid tumor targets including mesothelin for pancreatic and ovarian cancers and glypican-3 for hepatocellular carcinoma. The myeloid cell engineering market is heavily concentrated in solid tumor applications, reflecting the fundamental biological rationale that macrophages naturally infiltrate solid tumor microenvironments that T cells cannot access. This solid tumor focus distinguishes macrophage therapy from CAR-T therapy and positions it as a potentially complementary rather than competitive modality within the broader innate immune oncology landscape.
Competitive Landscape and Technology Platform Differentiation
The Macrophage Anticancer Therapy market is segmented as below:
Carisma
Myeloid Therapeutics
Inceptor Bio
Cell-Origin
Rocrock Bio
Shaanxi Jushi Kangji Biotechnology
Segment by Type
CD19
HER2
Others
Segment by Application
Solid Tumors
Non-Solid Tumors
The competitive landscape of the macrophage anticancer therapy market share distribution reflects a field populated by specialized biotechnology startups rather than large pharmaceutical incumbents—a pattern characteristic of emerging technology platforms where scientific risk remains substantial. Carisma Therapeutics, the field’s pioneer, has established a leading position through its proprietary CAR-M platform technology, adenoviral transduction methodology, and the most clinically advanced CAR-M product candidate. Myeloid Therapeutics has developed an alternative approach utilizing mRNA-based engineering for transient CAR expression. Inceptor Bio, Cell-Origin, and Rocrock Bio represent the growing competitive landscape. Shaanxi Jushi Kangji Biotechnology represents Chinese participation in macrophage therapy development.
Strategic Outlook: Complementary Positioning in the Immuno-Oncology Arsenal
The trajectory from USD 436 million to USD 635 million by 2032 captures the measured but strategically significant expansion of an emerging immunotherapy platform whose ultimate clinical and commercial potential depends on Phase II/III efficacy data. For biopharmaceutical executives, oncology investors, and cell therapy strategists, comprehensive market research confirms that macrophage anticancer therapy represents a distinctive immunological approach positioned at the frontier of innate immune cell engineering, with the potential to address solid tumor indications that have proven refractory to T cell-based immunotherapies.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
